Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lymphoma: Non-Hodgkin's Lymphoma

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

The purpose of this study is to test the safety & tolerability, describe any DLTs, & determine the MTD or highest protocol-defined doses for MEDI4736 as monotherapy & in combination w/ tremelimumab or AZD9150 in relapsed or refractory DLBCL.

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

The purpose of this study is to Evaluate the safety, tolerability, and DLTs of AGEN1884 in advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

The overall purpose of this study is to determine if JCAR017 is safe and effective as a treatment for adults with B-cell Non-Hodgkin Lymphomas that include Diffuse Large B-cell Lymphoma (Transformed DLBCL from indolent histology and Follicular Lymphoma Grade 3B) and Mantle Cell Lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Grades II to IV Acute Graft-Versus-Host Disease

The purpose of this study is to assess the safety and tolerability of INCB039110 in combination with corticosteroids in subjects with Grades II to IV acute graft-versus-host disease (GVHD).

Status: Accepting New Patients
Principal Investigator: John Galvin

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

The purpose of this research study is twofold: first, to identify the maximum tolerated dose, that is, the highest dose of the investigational study drug INCB052793 that does not cause unacceptable side effects; and second, to obtain information on the safety, effectiveness, and tolerability of INCB052793 in combination with standard therapies in treating advanced solid tumors and hematologic malignancies (blood cancers).

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)

The purpose of this research study is to see if Atorvastatin (generic for Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in participants receiving anthracycline based chemotherapy for breast cancer or lymphoma.

Status: Accepting New Patients
Principal Investigator: Daniel Lee

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

The purpose of this research is to evaluate the safety and tolerability of the investigational drug, INCB053914, and to select the doses that will be studied further in people with advanced cancers or diseases where cells grow too much.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation

This purpose of this study is to find out how safe and tolerable the study drug AG-881 is in patients with hematological cancers which does not respond to standard treatment. Patients diagnosed with the following types of blood cancers - Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) Myeloproliferative Neoplasm (MPN) or Angioimmunoblastic T-cell Lymphoma (AITL) may qualify for the study. The main purpose of the study is to identify and test the highest dose of the study drug (AG-881) that can be given safely to patients. This drug is designed to target two proteins known as Isocitrate Dehydrogenase (IDH1 and IDH2), which have been discovered to be critical for cancer cell growth by supporting its enhanced metabolic activity. Researchers have discovered that many types of blood cancers have mutations in this protein that causes it to become overactive. The study will mainly answer the following questions: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that gets into the blood stream at different time points and what it does to the body after being taken orally.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer.

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad it has on B-cell Lymphoma when given along with low-dose radiation therapy.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The purpose of this research study is to see if KPT-330 has any effects against your cancer.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Intergroup Randomized Phase II Four Arm Study In Patients >= 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB - R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV- R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB - LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV - LR)

The purpose of this study is twofold and has 2 phases of treatment, the induction (initial) phase and the consolidation (continuing) phase. In the induction phase the purpose is to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on mantle cell lymphoma compared to rituximab plus bendamustine alone. In the consolidation treatment phase, the purpose is to find out what effects, good and bad, continuing treatment after induction with lenalidomide plus rituximab has on lymphoma compared to continuing treatment with rituximab alone.

Status: Accepting New Patients
Principal Investigator: Jane Winter

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other Non-Hodgkin’s lymphomas, solid tumors and multiple myeloma

The purpose of this study is to see how well the study drug, GSK2816126, works and how safe it is, as a treatment for diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma which has not responded or has returned after other treatments.

Status: Accepting New Patients
Principal Investigator: Jane Winter

A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B cell Lymphoma and Follicular Lymphoma

The main purpose of this study is to look at the safety and tolerability of combinations of three new drugs (CC-122, CC-223, and CC-292) being developed to treat diffuse large B cell lymphoma (DLBCL). The study aims to identify the highest doses tolerated by subjects, which will help guide future research studies. A drug called rituximab, which is already approved and used as therapy for this this disease, will also be part of this study.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Sat - June 25, 2016 - 04:00 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.